Format: Keynote lecture and panel discussion
Keynote speaker:: Prof. Oskar Hansson, Lund University and Prof. …
Panel discussion participants: Prof Ansgar Felbecker, Neurologische Praxis St. Gallen, Prof. Oskar Hansson, Lund University
Chair: Prof. Andreas Papassotiropoulos
Description: This session will feature two keynote speakers, each addressing the topic from a unique perspective. One will discuss biomarkers for early diagnosis from a preclinical standpoint, while the other will provide clinical insights on treatment options, potentially sharing early experiences with the newly approved dementia drug, Lecanemab. This clinical perspective will delve into the practical challenges of these treatments, including their efficacy, tolerability, patient suitability and monitoring strategies.
Following the keynote lectures, a panel discussion will bring together experts from the industry, public sector and the keynote speakers to debate the new treatment options. This discussion is particularly timely as Lecanemab is expected to receive EMA approval in 2025, with potential introduction in Switzerland.
